EQT Explores Strategic Options for WS Audiology, Including Potential Copenhagen IPO

By [Your Name]
October 10, 2023

Private Equity Giant EQT Weighs Exit from Hearing Aid Leader WS Audiology

Global private equity firm EQT AB has enlisted investment banks to evaluate strategic options for WS Audiology, one of the world’s leading hearing aid manufacturers, including a potential initial public offering (IPO) in Copenhagen, according to sources familiar with the matter. The move signals EQT’s latest effort to capitalize on the booming hearing healthcare market, which has seen steady growth due to aging populations and increasing demand for advanced audiology solutions.

While no final decision has been made, an IPO would mark a significant milestone for WS Audiology, which was formed in 2019 through the merger of Denmark’s Widex and Germany’s Sivantos. The company has since expanded aggressively, now operating in over 125 countries with brands like Widex, Signia, and Rexton. A listing could value the business at several billion dollars, though market conditions will play a decisive role in timing.

Why WS Audiology Is a Prime Asset

WS Audiology has emerged as a key player in a rapidly consolidating industry dominated by a handful of major manufacturers, including Sonova, Demant, and GN Store Nord. The company reported €1.8 billion ($1.9 billion) in revenue for 2022, benefiting from strong demand for premium hearing aids equipped with AI-powered sound processing and Bluetooth connectivity.

The hearing aid market is projected to grow at a compound annual rate of 6-7% over the next decade, driven by demographic shifts—nearly 25% of people over 65 experience disabling hearing loss—and technological advancements that reduce stigma around hearing devices. WS Audiology has invested heavily in direct-to-consumer digital solutions, positioning itself as an innovator in a traditionally conservative sector.

EQT’s Exit Strategy: IPO or Trade Sale?

EQT, which acquired Sivantos in 2015 and later engineered the merger with Widex, is now exploring multiple exit routes. The hiring of investment banks suggests a dual-track process, where an IPO is weighed alongside potential trade sales to industry rivals or other private equity firms.

A Copenhagen listing would align with WS Audiology’s Danish roots and provide access to Europe’s deep capital markets. However, volatile equity conditions—particularly for healthcare-related IPOs—could push EQT toward a private sale. Major competitors like Sonova and Demant have been active in M&A, making them possible suitors should EQT opt for a trade deal.

Market Conditions and Investor Appetite

The timing of any transaction remains uncertain. While the IPO market has shown signs of revival in 2023 after a dismal 2022, macroeconomic headwinds—including rising interest rates and geopolitical instability—could delay plans. Hearing aid stocks have performed relatively well, however, given their defensive characteristics in uncertain economic climates.

Analysts suggest that WS Audiology’s strong brand portfolio and exposure to high-growth Asian markets could attract investor interest. “The hearing aid industry is resilient, with inelastic demand and pricing power,” said Lars Holmqvist, a healthcare analyst at Nordea Markets. “An IPO would give public investors exposure to a market with long-term structural growth drivers.”

What’s Next for WS Audiology?

Should EQT proceed with an IPO, WS Audiology would join a small but prestigious group of Scandinavian healthcare listings, including Denmark’s Genmab and Sweden’s Sobi. A successful debut could also spur further consolidation in the sector, as competitors look to bolster their market share.

For now, the company remains focused on innovation, recently launching a new line of rechargeable hearing aids with machine-learning capabilities. Whether under continued private ownership or public markets, WS Audiology appears well-positioned to capitalize on the growing global need for hearing solutions.

As EQT weighs its options, the coming months will reveal whether WS Audiology’s next chapter unfolds on the stock exchange or through a strategic acquisition. Either way, the hearing aid giant’s future looks set to make noise.